BioDelivery Sciences International, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioDelivery Sciences International, Inc.
EMA OKs Seven New Drugs Including First RSV Vaccine For Older Adults
GSK’s Arexvy vaccine for preventing lower respiratory tract disease caused by respiratory syncytial virus in adults aged 60 years and older is among the latest products that the European Medicines Agency said should be approved for use in the EU.
EMA Decision Time For GSK’s RSV Older Adult Vaccine & Roche’s Glofitamab For LBCL
A number of companies could soon find out whether the European Medicines Agency will back pan-EU marketing approval for their respective products.
Bold Plans Pivotal GI Cancer Studies After Phase II Success
The private Canadian biotech is advancing a first-in-class GRP78 inhibitor into Phase III studies in gastrointestinal cancers after interim Phase II data suggested potential to improve upon on standard-of-care efficacy.
After US Woes, Akebia Celebrates EU Nod For Vafseo
The US biotech is in the throes of an appeal to the FDA against the rejection of its HIF-PH inhibitor but regulators in the EU have looked more kindly on vadadustat, which will be sold as Vafseo.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Arius Pharmaceuticals
- Arius Two Inc
- Bioral Nutrient Delivery LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.